Serialously – Another Acquisition for Valeant

This serial acquirer is sticking with its strategy. The company’s sizeable debt burden makes this a risky proposition.

| More on:
The Motley Fool

Valeant Pharmaceuticals (TSX:VRX,NYSE:VRX) is back in the acquisition ring after announcing the $343.8 million purchase of Obagi Medical Products (NASDAQ:OMPI) yesterday.  Obagi is the 21st company Valeant has purchased since the beginning of 2011.  The $344 million brings total cash spent on acquisitions to $6.3 billion over this period.  Pretty amazing for a company that had a market cap of about $7 billion when the shopping spree began.

All clear

Obagi is a maker of skin care products that booked revenues of $120 million last year.  Valeant is not only acquiring these revenue generating products, but the company also believes that it can realize $40 million of cost saving synergies.  In addition, Obagi’s distribution channel is an attractive asset that Valeant can leverage with its growing portfolio of dermatology related products.

On the surface, this deal looks pretty clean if you’re a Valeant shareholder.  Neither the $120 million in revenue nor the $344 million purchase price are overly material to a company that had revenue of $3.5 billion in 2012 and more than $900 million in cash on hand at last report.  And, if Valeant can pad its bottom line by successfully integrating Obagi’s business and realizing the proposed synergies, downside appears minimal.

For now

Regardless of its materiality, the Obagi deal makes it very clear that Valeant is going to keep on buying things.  Valeant is a serial acquirer and has demonstrated phenomenal growth by implementing this strategy.  It has taken a couple of big swings, like the 2011 $2.6 billion acquisition of Medicis, but for the most part, the company has knocked out singles and doubles with its purchases – like Obagi.

However, these singles and doubles with the odd home run have placed a huge burden on Valeant’s balance sheet.  The company is loaded with financial risk.

But beware the big one

Beyond financial risk, another huge risk is lurking for Valeant shareholders.  Singles and doubles are fine for a while, but can only hold the serial acquirer’s interest for so long.  You can bet, somewhere out there lies a “company transforming” acquisition for Valeant.

Ask Hewlett-Packard shareholders how much fun these types of transactions are.  HP purchased Autonomy several years ago for $11 billion and promptly had to write-off $8.8 billion when Autonomy fell short of expectations.  HP shareholders were lucky that the company’s balance sheet was in sound enough shape to absorb such a massive hit.  Valeant simply does not have this luxury.  Overpaying for a transformational purchase could mean the end.

The Foolish Bottom Line

Just like a leveraged investor, highly levered companies can blow up when faced with even the slightest bit of adversity.  The combination of a highly leveraged balance sheet and possibility of overpaying for a massive acquisition at some point makes this Fool highly wary of Valeant’s long-term viability.

We have created a special free report that provides an overview of five Canadian companies with negligible financial risk and exceptionally bright futures.  To receive this report, simply click here and we will deliver it to you, absolutely free!

Follow us on Twitter and Facebook for the latest in Foolish investing.

Fool contributor Iain Butler does not own shares in any of the companies mentioned in this report at this time.  The Motley Fool has no positions in the stocks mentioned above.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

More on Investing

Piggy bank in autumn leaves
Dividend Stocks

CPP Pensioners: You’re Getting an Inflation Increase in 2025

CPP benefits increase with inflation, but this stock's dividends can outpace even that.

Read more »

Middle aged man drinks coffee
Retirement

Here’s the Average RRSP Balance at Age 54 for Canadians (and How to Boost Yours)

Are you on track for a comfortable retirement? See how your savings stack up.

Read more »

Circuit board with glowing lines
Investing

AI Investors: 2 ‘Sleep Easy’ Dividend Stocks to Buy in October

Fortis (TSX:FTS) stock and another top dividend play that could be a nice fit for AI investors looking to diversify…

Read more »

AI powered robotic finger touching human finger
Investing

What Is Artificial General Intelligence (AGI)?

An AGI system would be capable of thinking and reasoning the way that humans do without the need for human…

Read more »

coins jump into piggy bank
Dividend Stocks

Invest $15,000 in This Dividend Stock for $61 in Monthly Passive Income

Monthly passive income is well within reach, especially when you have a solid dividend stock like this on hand.

Read more »

RRSP (Registered Retirement Savings Plan) on wooden blocks and Canadian one hundred dollar bills.
Dividend Stocks

RRSP: 2 Reliable Canadian Dividend Stocks to Own for Decades

These stocks offer high yields and a shot at decent capital gains.

Read more »

concept of real estate evaluation
Dividend Stocks

Invest $7000 in This Dividend Stock to Make $600 in Passive Income

Looking to make monthly passive income? Timbercreek Financial (TSX:TF) stock's 8.6% dividend yield could turn into a steady stream of…

Read more »

woman analyze data
Investing

3 Top Stocks to Buy in October for Value-Hunting Canadians

Given their healthy long-term growth potential and discounted stock prices, I am bullish on these three TSX stocks.

Read more »